Clinical trial readout dates for BioNTech SE, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 BNT162b2 Vaccine COVID-19; SARS-COV-2 Infection · NCT07300839 | September 2026 Primary data collected |
| Phase 3 BNT162b2 (2025/2026 formulation) COVID-19; SARS-COV-2 Infection · NCT07222384 | July 2026 Primary data collected |
| Phase 3 Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2 · NCT05543616 | July 2026 Primary data collected |
| Phase 3 BNT162b2 COVID-19 Vaccines · NCT07798648 | April 2027 Recruiting |
| Phase 2 BNT327 Dose Level 1 (DL1) Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer · NCT06449209 | June 2027 Ongoing |
| Phase 2 BNT166a Mpox (Monkeypox); Smallpox · NCT07379580 | June 2027 Recruiting |
| Phase 1/2 BNT3212 Advanced Solid Tumor · NCT07147348 | November 2027 Recruiting |
| Phase 2 Pumitamig Pancreatic Ductal Adenocarcinoma (PDAC) · NCT07255404 | December 2027 Recruiting |
| Phase 2 Pumitamig Recurrent Glioblastoma · NCT07297212 | January 2028 Recruiting |
| Phase 1/2 BNT326 Advanced Solid Tumor · NCT07070232 | March 2028 Recruiting |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 RO7198457 intravenous (IV) Colorectal Cancer Stage II; Colorectal Cancer Stage III · NCT04486378 | November 2026 Ongoing |